Publication Delays Impact Careers of Early-Career Researchers

By João L. Carapinha

May 19, 2025

The article “Dear editors, your publication delays are damaging our careers” by Chia-Hsuan Hsu highlights how publication delays hurt careers, especially for early-career researchers. With publication records key for jobs and tenure, slow editorial processes stall academic progress. The author shares waiting 18 months for a decision, blaming poor reviewer recruitment. This calls on editors to improve efficiency.

The Detrimental Impact of Delays

The article notes that publication delays impact careers by harming early-career researchers. Delays can cost job and funding chances, hindering growth. East Asia heavily weighs publication history in evaluations, making delays more damaging than in regions valuing broader contributions. Bottlenecks often stem from poor reviewer recruitment and communication, not scientific merit. While preprints speed up sharing findings, they often don’t count for career evaluations in Japan and Taiwan.

The article reflects broader issues in publishing and evaluation. The global academic system overvalues publications for hiring and funding, pressuring early-career researchers into a publish or perish culture. A few big publishers control the market while unpaid editorial labor leads to slow, profit-driven processes that clash with researchers’ needs. Delays often arise from reviewer shortages and overworked editors, hurting researchers needing timely output.

Proactive Solutions for a Changing Landscape

  • Reforming Academic Evaluation: Reports suggest valuing preprints and datasets more, but until reforms spread, early-career researchers suffer.
  • Innovative Peer Review Models: Open peer review and reviewer incentives could help, needing publisher and institutional cooperation.
  • Policy Recommendations: Health agencies and consortia could recognize preprints in evaluations, easing delays’ harm.

In summary, the article shows how publication delays hurt careers. Fixing this needs changes from editors, publishers, and institutions to ensure fair opportunities. For deeper insights, explore the source material.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.